DYNE-251 is under clinical development by Dyne Therapeutics and currently in Phase II for Duchenne Muscular Dystrophy. According to GlobalData, Phase II drugs for Duchenne Muscular Dystrophy have a 61% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how DYNE-251’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

DYNE-251 overview

DYNE-251 is under development for the treatment of Duchenne muscular dystrophy. The therapeutic candidate consists of an antibody (Fab) that targets the human transferrin receptor 1 (hTfR1) conjugated to phosphorodiamidate morpholino oligomer (PMO) through valine-citrulline linker and is being developed based on FORCE platform which skips exon 51 of the dystrophin gene. It is administered through intravenous route.

Dyne Therapeutics overview

Dyne Therapeutics is a clinical-stage muscle disease company that develops innovative therapeutics for genetically driven diseases. The company develops drugs by using the FORCE platform. Its pipeline products include DYNE-101, which consists of a proprietary Fab conjugated to an antisense oligonucleotide (ASO) that treats myotonic dystrophy type 1 (DM1); DYNE-251, which consists of a phosphorodiamidate morpholino oligomer (PMO) conjugated to a proprietary Fab that treats Duchenne muscular dystrophy (DMD); DYNE-301 targets DUX4 that treats facioscapulohumeral muscular dystrophy (FSHD). The company also evaluating programs to treat rare skeletal, cardiac and metabolic muscle diseases. Dyne Therapeutics is headquartered in Waltham, Massachusetts, the US.

For a complete picture of DYNE-251’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.